Table 5. Sex differences in change in EPA and DHA in plasma fractions, cells and AT following 12-months supplementation with EPA+DHA.
EPA1 | P 2 | DHA1 | P 2 | |
---|---|---|---|---|
Plasma PC | −0.07 [−0.37, 0.22] | 0.63 | −0.16 [−0.62, 0.30] | 0.50 |
Plasma CE | −0.16 [−0.43, 0.11] | 0.25 | 0.08 [−0.02, 0.12] | 0.10 |
Plasma NEFA | 0.04 [−0.06, 0.15] | 0.42 | 0.23 [−0.22, 0.69] | 0.79 |
Plasma TAG | −0.30 [−0.60, −0.01] | 0.05 | −0.21 [−0.56, 0.14] | 0.25 |
MNC | −0.16 [−0.42, 0.11] | 0.26 | 0.03 [−0.22, 0.29] | 0.82 |
RBC | −0.51 [−1.40, 0.37] | 0.26 | 0.36 [−0.18, 0.90] | 0.19 |
PLAT | −0.25 [−0.53, 0.03] | 0.08 | −0.09 [−0.29, 0.11] | 0.38 |
BU | −0.10 [−2.01, 1.82] | 0.93 | 0.07 [−0.11, 0.26] | 0.44 |
AT | 0.02 [−0.02, 0.06] | 0.25 | 0.00 [−0.05, 0.05] | 0.99 |
Data are mean difference [95% CI] in the change in EPA or DHA expressed as percentage of total fatty acids female compared to male adjusted for treatment group, compliance and BMI.
Analysis is change regressed on male vs. female, adjusted for treatment group, compliance and BMI.